Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
Stephen Barnhill, chairman and CEO of HDC, said: “We are very pleased to partner with Abbott on commercialization of these exciting new molecular diagnostic tests for prostate cancer. Abbott is an innovative leader in the fast paced, high growth medical technology space serving customers around the world.”